BCAX

Bicara TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$34.00

Analysis reference price unavailable

Analysis 2026-09-25 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$22.00

Analysis reference price unavailable

Analysis 2026-09-25 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$10.00

Analysis reference price unavailable

Analysis 2026-09-25 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-25

AI commentary

Company-source milestones support a cautiously constructive, catalyst-dependent view, not a high-conviction momentum call. Independent coverage in the packet is thin; reliable recent analyst revisions, options skew, short interest and social-sentiment measurements were unavailable. Numeric zeros above denote unavailable measurements, not observed neutral readings. No post-release price reaction or earnings-consensus surprise is asserted.

RankAlpha Sentiment Codex - 2026-09-25

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31eventMetastatic colorectal cancer cohort dataHigh impact

The company plans second-half 2026 Phase 1b data for ficerafusp alfa, alone and with pembrolizumab, in a specified third-line-or-later metastatic colorectal cancer cohort. The data could test whether the lead asset has potential beyond head-and-neck cancer [#IR-2026-08-11] ([company release](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-second-quarter-2026-progress-and)).

2026-12-31catalystFORTIFI-HN01 enrollment milestoneHigh impact

Bicara expects its pivotal Phase 3 head-and-neck cancer trial to be substantially enrolled by year-end 2026. Timely enrollment would support the planned interim analysis; slippage would weaken that timeline [#IR-2026-08-11] ([company release](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-second-quarter-2026-progress-and)).

2027-06-30catalystFORTIFI-HN01 interim analysisHigh impact

Bicara targets topline interim results in mid-2027. Its reported three-year Phase 1/1b follow-up is encouraging, but the pivotal randomized study must establish whether that signal holds [#IR-2026-08-11] ([company release](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-second-quarter-2026-progress-and)).

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-25 • Updated nightlySource: Internal modelMethodology